Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Gynecologic Oncology

Treatment for Locally Advanced & Metastatic Cervical Cancer

At a Glance

Locally advanced cervical cancer is usually treated with chemoradiation—weekly cisplatin, external-beam radiation, and brachytherapy—while recurrent or metastatic disease may require systemic medicines such as pembrolizumab, bevacizumab, or tisotumab vedotin.

When cervical cancer is diagnosed at a later stage, the focus of treatment shifts toward a combination of powerful therapies. Whether the goal is to cure the cancer (locally advanced) or to manage it and improve quality of life (metastatic or recurrent), understanding the “why” behind each medication and procedure is essential for your journey.

Locally Advanced Cancer (Stages IB3 to IVA)

“Locally advanced” means the cancer has grown large within the cervix or spread to nearby pelvic tissues or lymph nodes, but has not traveled to distant organs like the lungs or liver [1].

The Definitive Standard: Chemoradiation

The standard treatment for locally advanced disease is concurrent chemoradiation. This is a two-pronged approach [2][3]:

  1. Weekly Chemotherapy: Low-dose cisplatin is typically given once a week to act as a “sensitizer,” making the cancer cells more vulnerable to radiation [2].
  2. External Beam Radiation (EBRT): Precise X-ray beams are aimed at the pelvis daily for about five weeks [2].

Brachytherapy: An Essential Component

Integrated during or after EBRT, a specialized form of internal radiation called brachytherapy is an essential part of definitive curative radiation. This is not an optional “extra” or a backup plan; it is a critical part of the cure [2].

  • How it works: A radioactive source is placed directly inside or very near the tumor for a short time. This allows a very high dose of radiation to hit the cancer while sparing the nearby bladder and rectum [2][4].
  • The 56-Day Target: Research shows that for the best results, the overall treatment time (EBRT plus brachytherapy) should generally be kept within about 56 days (8 weeks) when medically feasible, though your care team will manage any unavoidable delays [2][5].

New Frontiers: Adding Pembrolizumab

Recent results from the KEYNOTE-A18 trial have introduced a third prong for specific high-risk patients. Adding the immunotherapy drug pembrolizumab to the standard chemoradiation plan has been shown to improve survival rates. Eligibility depends on your specified FIGO stage, nodal status, local approvals, and any contraindications like autoimmune disease [1][6].

Recurrent or Metastatic Cancer

Recurrence is not automatically assigned as Stage IVB. An isolated pelvic recurrence may sometimes be treated with curative-intent surgery or radiation. However, if the cancer has spread to distant organs (metastatic Stage IVB) or is widely recurrent, the focus moves to systemic therapy—treatments that travel through the entire bloodstream.

First-Line Immunotherapy Combinations

The choice of first-line therapy depends on your tumor’s PD-L1 CPS, kidney function, bleeding risk, and prior therapies.

  • Pembrolizumab (Keytruda): This drug helps your immune system recognize and kill cancer cells. It is especially effective if your tumor is “PD-L1 positive” (meaning it has a specific protein score, or CPS, of 1 or higher) [7][8]. Important: Immunotherapy can cause immune-related pneumonitis, colitis, or hepatitis; report severe diarrhea, breathing problems, or unusual fatigue promptly.
  • Bevacizumab (Avastin): This drug cuts off the blood supply to the tumor. While it helps many patients live longer, it carries risks of hypertension, proteinuria, thrombosis, bleeding, impaired wound healing, and fistulas (abnormal openings between the vagina and the bowel or bladder) [9][10].
    • High-Risk Warning: The risk of a fistula is much higher for patients who have had pelvic radiation in the past [11][12].

Subsequent Options: Tisotumab Vedotin

If the first combination stops working, your doctor may recommend tisotumab vedotin (Tivdak) [13][14]. This is a “targeted” drug that carries a small dose of chemotherapy directly to the cancer cells. It has very specific side effects that require a strict safety plan:

  • Ocular (Eye) Toxicity: This drug can cause severe dry eye, inflammation, or corneal ulcers. You must undergo baseline and ongoing ophthalmic examinations and follow a strict eye-care plan involving specific cooling masks and three different types of eye drops (steroids, vasoconstrictors, and lubricants). You must avoid contact lenses when directed and urgently report any eye pain, redness, or vision change [15][16].
  • Bleeding: Nosebleeds and other bleeding events are common [17].
  • Peripheral Neuropathy: Numbness, tingling, or weakness in the hands and feet can occur and may require your doctor to lower the dose or pause treatment [17][18].

Every step in treating advanced cervical cancer is a balance between fighting the disease and maintaining your well-being. Regular conversations with your team about these specific risks are the best way to navigate your care [19].

Common questions in this guide

What is the usual treatment for locally advanced cervical cancer?
The usual definitive treatment is concurrent chemoradiation. It typically combines weekly low-dose cisplatin with daily external-beam radiation and brachytherapy, an internal radiation treatment aimed near the tumor. When medically feasible, the full course is generally planned to finish within about 56 days.
Why is brachytherapy part of cervical cancer treatment?
Brachytherapy places a radioactive source inside or near the tumor for a short time. It delivers a concentrated dose while limiting exposure to the nearby bladder and rectum. It is an essential part of definitive radiation treatment, not simply an optional add-on.
Could pembrolizumab be added to my chemoradiation?
Pembrolizumab may be added for selected patients with high-risk locally advanced cervical cancer. Eligibility depends on factors such as FIGO stage, lymph-node status, local approvals, and medical issues such as some autoimmune diseases. Your oncology team must determine whether the potential benefit outweighs the risks.
How is recurrent or metastatic cervical cancer treated?
An isolated pelvic recurrence may sometimes be treated with surgery or radiation with the goal of cure. When cervical cancer has spread to distant organs or is widely recurrent, treatment usually relies on systemic medicines that travel through the bloodstream. The choice may depend on PD-L1 CPS, kidney function, bleeding risk, and prior treatment.
What does PD-L1 CPS mean for immunotherapy?
PD-L1 CPS is a score showing how much of the PD-L1 protein is present in the tumor and surrounding cells. A CPS of 1 or higher is described on this page as PD-L1 positive and can support use of pembrolizumab in appropriate settings. The score is only one part of treatment selection.
What are the main risks of bevacizumab?
Bevacizumab can cause high blood pressure, protein in the urine, blood clots, bleeding, and slower wound healing. It can also cause a fistula, an abnormal connection between the vagina and bladder or bowel. Previous pelvic radiation increases this fistula risk, so tell your team about any radiation history.
What monitoring is needed with tisotumab vedotin?
Tisotumab vedotin requires a baseline and ongoing eye examinations plus a prescribed eye-care plan, which may include cooling and several types of eye drops. It can cause serious eye problems, bleeding, and numbness or tingling in the hands and feet. Report eye pain, redness, vision changes, or worsening nerve symptoms promptly.

Get notified when new evidence is published on cervical cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

    Lorusso D, Xiang Y, Hasegawa K, et al.

    Lancet (London, England) 2024; (404(10460)):1321-1332 doi:10.1016/S0140-6736(24)01808-7.

    PMID: 39288779
  2. 2

    Radiation therapy for cervical cancer in Uganda: a practice guideline.

    Kibudde S, Kavuma A, Abal B, et al.

    Ecancermedicalscience 2025; (19()):1999 doi:10.3332/ecancer.2025.1999.

    PMID: 41561518
  3. 3

    Impact of Patient Selection on Real-World Outcomes by Using the EMBRACE-II Treatment Protocol in Locally Advanced Cervical Cancer.

    Lindegaard JC, Kirisits C, Schmid MP, et al.

    International journal of radiation oncology, biology, physics 2025; (123(3)):669-680 doi:10.1016/j.ijrobp.2025.05.068.

    PMID: 40460895
  4. 4

    CT versus MRI for Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: A Propensity Score-Matched Analysis.

    Nagar A, Samanta A, Chopra S, et al.

    International journal of radiation oncology, biology, physics 2026; (125(4)):1111-1120 doi:10.1016/j.ijrobp.2026.01.041.

    PMID: 41692354
  5. 5

    Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer.

    Korenaga TK, Yoshida EJ, Pierson W, et al.

    Gynecologic oncology 2022; (164(2)):348-356 doi:10.1016/j.ygyno.2021.11.015.

    PMID: 34865860
  6. 6

    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.

    Lorusso D, Xiang Y, Hasegawa K, et al.

    Lancet (London, England) 2024; (403(10434)):1341-1350 doi:10.1016/S0140-6736(24)00317-9.

    PMID: 38521086
  7. 7

    Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial.

    Hasegawa K, Colombo N, Tewari KS, et al.

    JAMA oncology 2026; doi:10.1001/jamaoncol.2026.3547.

    PMID: 42720936
  8. 8

    Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.

    Colombo N, Dubot C, Lorusso D, et al.

    The New England journal of medicine 2021; (385(20)):1856-1867 doi:10.1056/NEJMoa2112435.

    PMID: 34534429
  9. 9

    Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

    Tewari KS, Sill MW, Penson RT, et al.

    Lancet (London, England) 2017; (390(10103)):1654-1663 doi:10.1016/S0140-6736(17)31607-0.

    PMID: 28756902
  10. 10

    Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.

    Chuai Y, Rizzuto I, Zhang X, et al.

    The Cochrane database of systematic reviews 2021; (3()):CD013348 doi:10.1002/14651858.CD013348.pub2.

    PMID: 33661538
  11. 11

    Gastrointestinal/genitourinary perforation and fistula formation with or without bevacizumab in patients with previously irradiated recurrent cervical cancer: a Korean multicenter retrospective study of the Gynecologic Oncology Research Investigators Collaboration (GORILLA) group (GORILLA-1001).

    Hwang WY, Chang SJ, Kim HS, et al.

    BMC cancer 2022; (22(1)):603 doi:10.1186/s12885-022-09695-x.

    PMID: 35655188
  12. 12

    Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.

    Redondo A, Colombo N, McCormack M, et al.

    Gynecologic oncology 2020; (159(1)):142-149 doi:10.1016/j.ygyno.2020.07.026.

    PMID: 32763109
  13. 13

    Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.

    Vergote I, González-Martín A, Fujiwara K, et al.

    The New England journal of medicine 2024; (391(1)):44-55 doi:10.1056/NEJMoa2313811.

    PMID: 38959480
  14. 14

    A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin.

    Luu K, Chu A, Chang B

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023; (29(2)):441-449 doi:10.1177/10781552221139775.

    PMID: 36415085
  15. 15

    Mitigation and management strategies for ocular events associated with tisotumab vedotin.

    Kim SK, Ursell P, Coleman RL, et al.

    Gynecologic oncology 2022; (165(2)):385-392 doi:10.1016/j.ygyno.2022.02.010.

    PMID: 35277279
  16. 16

    Ocular surface disease related to tisotumab vedotin-tftv.

    Lent-Schochet D, Tauber S, Seagrave Z, et al.

    Gynecologic oncology reports 2025; (57()):101676 doi:10.1016/j.gore.2025.101676.

    PMID: 39877468
  17. 17

    Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.

    Coleman RL, Lorusso D, Gennigens C, et al.

    The Lancet. Oncology 2021; (22(5)):609-619 doi:10.1016/S1470-2045(21)00056-5.

    PMID: 33845034
  18. 18

    Tisotumab Vedotin Safety and Tolerability in Clinical Practice: Managing Adverse Events.

    Arn CR, Halla KJ, Gill S

    Journal of the advanced practitioner in oncology 2023; (14(2)):139-152 doi:10.6004/jadpro.2023.14.2.4.

    PMID: 37009403
  19. 19

    Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.

    Randall L, Xiang Y, Matsumoto T, et al.

    Gynecologic oncology 2025; (199()):88-95 doi:10.1016/j.ygyno.2025.06.003.

    PMID: 40592026

This page is for informational purposes only and does not constitute medical advice. It explains treatment options and risks for advanced cervical cancer; discuss your stage, test results, and side effects with your oncology team.

Guide contents cervical cancer
Research & Literature
03 Treatment for Early-Stage Cervical Cancer 05 Managing Side Effects and Survivorship Quality of Life